These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 39147143)

  • 21. Genetic barrier to resistance: a critical parameter for efficacy of neutralizing monoclonal antibodies against SARS-CoV-2 in a nonhuman primate model.
    Stahl-Hennig C; Peter AS; Cordsmeier A; Stolte-Leeb N; Vestweber R; Socher E; Merida SA; Sauermann U; Bleyer M; Fraedrich K; Grunwald T; Winkler TH; Ensser A; Jäck H-M; Überla K
    J Virol; 2024 Jul; 98(7):e0062824. PubMed ID: 38899895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of high affinity monoclonal antibodies against SARS-CoV-2 variant infection using a DNA prime-protein boost strategy.
    Chiang CY; Chen MY; Hsu CW; Liu CY; Tsai YW; Liao HC; Yan JY; Chuang ZS; Wang HI; Pan CH; Yu CY; Yu GY; Liao CL; Liu SJ; Chen HW
    J Biomed Sci; 2022 Jun; 29(1):37. PubMed ID: 35681239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants.
    Wang K; Jia Z; Bao L; Wang L; Cao L; Chi H; Hu Y; Li Q; Zhou Y; Jiang Y; Zhu Q; Deng Y; Liu P; Wang N; Wang L; Liu M; Li Y; Zhu B; Fan K; Fu W; Yang P; Pei X; Cui Z; Qin L; Ge P; Wu J; Liu S; Chen Y; Huang W; Wang Q; Qin CF; Wang Y; Qin C; Wang X
    Nature; 2022 Mar; 603(7903):919-925. PubMed ID: 35090164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid and Flexible Platform To Assess Anti-SARS-CoV-2 Antibody Neutralization and Spike Protein-Specific Antivirals.
    Stelitano D; Weisberg SP; Goldklang MP; Zhu Y; Bovier FT; Kalantarov GF; Greco G; Decimo D; Franci G; Cennamo M; Portella G; Galdiero M; Mathieu C; Horvat B; Trakht IN; Moscona A; Whitt MA; Porotto M
    mSphere; 2021 Aug; 6(4):e0057121. PubMed ID: 34319126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition.
    Kramer KJ; Johnson NV; Shiakolas AR; Suryadevara N; Periasamy S; Raju N; Williams JK; Wrapp D; Zost SJ; Walker LM; Wall SC; Holt CM; Hsieh CL; Sutton RE; Paulo A; Nargi RS; Davidson E; Doranz BJ; Crowe JE; Bukreyev A; Carnahan RH; McLellan JS; Georgiev IS
    Cell Rep; 2021 Oct; 37(1):109784. PubMed ID: 34592170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody.
    Maruyama S; Wada D; Kanayama S; Shimazu H; Miyano Y; Inoue A; Kashihara M; Okuda K; Saito F; Nakamori Y; Ishii K; Kuwagata Y
    BMC Infect Dis; 2024 Jul; 24(1):715. PubMed ID: 39039440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics.
    Zhao S; Zhang H; Yang X; Zhang H; Chen Y; Zhan Y; Zhang X; Jiang R; Liu M; Liu L; Chen L; Tang W; Peng C; Gao X; Zhang Z; Shi Z; Gong R
    Nat Commun; 2021 Aug; 12(1):4887. PubMed ID: 34373446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries.
    Yuan TZ; Garg P; Wang L; Willis JR; Kwan E; Hernandez AGL; Tuscano E; Sever EN; Keane E; Soto C; Mucker EM; Fouch ME; Davidson E; Doranz BJ; Kailasan S; Aman MJ; Li H; Hooper JW; Saphire EO; Crowe JE; Liu Q; Axelrod F; Sato AK
    MAbs; 2022; 14(1):2002236. PubMed ID: 34967699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
    Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
    PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.
    Oladunni FS; Park JG; Chiem K; Ye C; Pipenbrink M; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Apr; 290():114084. PubMed ID: 33513380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
    Atyeo C; Slein MD; Fischinger S; Burke J; Schäfer A; Leist SR; Kuzmina NA; Mire C; Honko A; Johnson R; Storm N; Bernett M; Tong P; Zuo T; Lin J; Zuiani A; Linde C; Suscovich T; Wesemann DR; Griffiths A; Desjarlais JR; Juelg BD; Goudsmit J; Bukreyev A; Baric R; Alter G
    JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33427208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Kreye J; Reincke SM; Kornau HC; Sánchez-Sendin E; Corman VM; Liu H; Yuan M; Wu NC; Zhu X; Lee CD; Trimpert J; Höltje M; Dietert K; Stöffler L; von Wardenburg N; van Hoof S; Homeyer MA; Hoffmann J; Abdelgawad A; Gruber AD; Bertzbach LD; Vladimirova D; Li LY; Barthel PC; Skriner K; Hocke AC; Hippenstiel S; Witzenrath M; Suttorp N; Kurth F; Franke C; Endres M; Schmitz D; Jeworowski LM; Richter A; Schmidt ML; Schwarz T; Müller MA; Drosten C; Wendisch D; Sander LE; Osterrieder N; Wilson IA; Prüss H
    Cell; 2020 Nov; 183(4):1058-1069.e19. PubMed ID: 33058755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Heterologous Challenge Rescues the Attenuated Immunogenicity of SARS-CoV-2 Omicron BA.1 Variant in Syrian Hamster Model.
    Ma J; Liu X; Zhou M; Chen P; Chen R; Wang J; Zhu H; Wu K; Ye J; Zhang Y; Yuan Q; Tang Q; Yuan L; Cheng T; Guan Y; Xia N
    J Virol; 2023 Feb; 97(2):e0168422. PubMed ID: 36651747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
    Gu C; Cao X; Wang Z; Hu X; Yao Y; Zhou Y; Liu P; Liu X; Gao G; Hu X; Zhang Y; Chen Z; Gao L; Peng Y; Jia F; Shan C; Yu L; Liu K; Li N; Guo W; Jiang G; Min J; Zhang J; Yang L; Shi M; Hou T; Li Y; Liang W; Lu G; Yang C; Wang Y; Xia K; Xiao Z; Xue J; Huang X; Chen X; Ma H; Song D; Pan Z; Wang X; Guo H; Liang H; Yuan Z; Guan W; Deng SJ
    MAbs; 2021; 13(1):1930636. PubMed ID: 34097570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.